PPT-An alternative to warfarin for patients with

PE Author Anne Mounsey MD University of North Carolina PURL Journal Club Documents Included Instructions Speaker Notes Including Citation to Original Article Journal Club Worksheet Published PURL. versus Warfarin Therapy for Prevention of Stroke . in Patients with Atrial Fibrillation: A Randomized . Non-Inferiority Trial. David R. Holmes, MD. Vivek Y. Reddy, MD. Zoltan G. Turi, MD. Shephal K. Doshi, MD. Nicolas Novitzky. The Ideal Oral Anticoagulant. Ideally, an oral anticoagulant would: . Have high . efficacy. in reducing thromboembolic events. Reach . therapeutic levels . within several hours. Oral. د. حسين محمد جمعة . اختصاصي الامراض الباطنة . البورد العربي . كلية طب الموصل . 2010. Anticoagulant drugs. Anticoagulant drugs can be divided into two categories: oral and . Northlakes. Community Clinic. Minong, WI. Novel Anticoagulants:. Who Needs an INR Anymore?. Apixaban. (. Eliquis. ):. Approved in 2014. Rivaroxaban. (. Xarelto. ):. Approved in 2011. Dabigatran. (. EVI. dence. on . S. troke prevention . I. n patients with . a. T. rial. Fibrillation in the . U. nited . S. tates . Craig I. . Coleman. , . Matthias . Antz. , . Edgar . Simard, . Thomas . Evers, . Kevin . Dabigatran . Etexilate versus Warfarin in Patients Undergoing . Catheter . Ablation of Atrial Fibrillation: . The RE-CIRCUIT™ . Study. Hugh Calkins, . M.D.,. 1. Stephan . Willems. , M.D., Atul . Verma. , MD, PhD . Monday Morning Conference. Oct 4, 2010. Rivaroxaban. Dabigatran. Classes. Unfractionated. heparin. Direct thrombin inhibitors. Low molecular weight heparins, . fondiparinux. Vitamin K antagonists, Inhibiting clotting factors: II, VII, IX, X. Fred V. Plapp MD PhD. Pathology and Laboratory Medicine. Kansas University Medical Center. Financial Disclosure. Educational Objectives. Discuss intracerebral hemorrhage prevalence and etiologies. Review anticoagulation by warfarin and anti-Factor . Advantages of NOACs. No INR monitoring required. No bridging required . Easier to manage around surgical procedures. Convenient for rural patients or those with other barriers to . clinic . visits. Fewer. Kourosh. . Sadeghi. Tehran University of medical sciences. New Oral Anticoagulants (NOACs). Available in Iran. NOACs. Clinical Trials. RE-LY Study. 951 . clinical . centers in . 44 . countries, . Non-inferiority trial, 18,113 patients, fixed doses of dabigatran 110 mg or 150 mg twice daily — or, in an un-blinded fashion, adjusted-dose warfarin. . hip fractures. Dr Linda Xu . linda.xu@health.nsw.gov.au. Dr Nichola Boyle . Prof LeCouteur. Concord Repatriation General Hospital, NSW Australia. Background. Hip fracture most costly fracture type based on “per fracture” basis. atrophiclichen sclerosusWhat is the difference between atrophicginitis and lichen sclerosus? What are thetreatments?Atrophic VaginitisAtrophic vaginitis is a thinning of the epitheli-um, usually secon 1 COUMADIN Tablets for oralLactose, starch and magnesium stearate 1 mg: D&C Red No. 6 Barium Lake 2 mg: FD&C Blue No. 2 Aluminum Lake and FD&C Red No. 40 Aluminum Lake 2-1/2 mg: D&C Yellow No. 10 WHAT’S NEW?. Savino . Sciascia. , MD, PhD. Center of Research of Immunopathology and Rare Diseases-CMID. University of Torino. AADEA. Cordoba, Feb 2018. Agenda. What. to do . when. . anticoagulation.